TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US9532999B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 20, 2015 |
| Grant date | Jan 3, 2017 |
| Priority date | — |
| Expiry date | May 20, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/7034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.